Helius Medical Technologies’ (HSDT) “Hold” Rating Reiterated at Maxim Group

Maxim Group reissued their hold rating on shares of Helius Medical Technologies (NASDAQ:HSDT) in a report issued on Wednesday, Marketbeat Ratings reports.

Helius Medical Technologies Stock Down 1.8 %

Helius Medical Technologies stock opened at $0.54 on Wednesday. The company’s fifty day simple moving average is $0.70 and its 200-day simple moving average is $1.62. Helius Medical Technologies has a 12 month low of $0.37 and a 12 month high of $9.50. The stock has a market cap of $1.60 million, a P/E ratio of -0.04 and a beta of 1.60.

Helius Medical Technologies (NASDAQ:HSDT) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.14). Helius Medical Technologies had a negative net margin of 1,487.54% and a negative return on equity of 258.06%. The company had revenue of $0.18 million for the quarter. During the same quarter in the prior year, the company posted ($3.00) EPS.

Institutional Investors Weigh In On Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC acquired a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned about 4.39% of Helius Medical Technologies at the end of the most recent quarter. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.